The Federal Circuit reversed the District of Delaware’s decision to invalidate Orexo’s opioid treatment patent as obvious because obviousness was not proved by clear and convincing evidence. Specifically, the Court pointed to the absence of a teaching in the prior art that citric acid could serve as a carrier particle for the drug agonist. The Court also noted that the lower court improperly discounted evidence of objective indicia of nonobviousness.
The post Federal Circuit Reverses, Finds Opioid Addiction Treatment Patent Nonobvious appeared first on IPWatchdog.com | Patents & Patent Law.
Recent Posts
- Other Barks & Bites for Friday, January 24: CAFC Reverses RDOE Noninfringement Ruling; EU Challenges China’s Global SEP Rate Setting Practices; and SCOTUS Nixes Cert Petition Challenging PTAB Paneling
- Trump Hiring Freeze Leaves USPTO Backlog Attack Plan in Limbo
- Five Questions the New Commerce Secretary Should Ask When Vetting a USPTO Director
- The Law and Politics of Drug Price Controls and Pharmaceutical Innovation
- Trump Names Coke Stewart Acting Director of the USPTO